Use of immature oocytes in infertility treatment
저자
발행기관
학술지명
권호사항
발행연도
2010
작성언어
English
주제어
자료형태
학술저널
발행기관 URL
수록면
4-5(2쪽)
제공처
Since the first case of pregnancy by in vitro matured oocyte was reported (Cha et al., 1991), in vitro maturation (IVM) could be used as an alternative choice for the treatment of infertile women with polycystic ovary syndrome (PCOS) and poor responders to ovarian stimulation and as one of the strategies for fertility preservation (Chian, 2004). Immature oocyte retrieval followed by IVM is a promising potential treatment option, especially for women who are infertile through PCOS. Although the pregnancy and implantation rates of IVM treatment are not as high as conventional IVF treatment, IVM treatment has many advantages for infertile women with PCOS, because this group of patients is extremely sensitive to stimulation with exogenous gonadotropins and is at increased risk of developing ovarian hyperstimulation syndrome (OHSS). Different protocols have been used before immature oocyte retrieval, indicating that there are beneficial effects with FSH or LH priming on oocyte maturation. To date, the clinical pregnancy and implantation rates obtained from IVM treatment in infertile women with PCOS are approximately 30-35% and 10-15% respectively (Chian, 2004). The clinical outcome has substantially improved in recent years with pregnancy rates between 20 and 54% and the postnatal follow-up studies of the children have been reassuring (Suikkari, 2008). Currently, more than 400 healthy infants have been reported with IVM method (Jurema and Nogueira, 2006; Suikkari, 2008). Although good results have been reported by some clinics, IVM has not yet become a mainstream fertility treatment. The most important reason for this is the lower chance of a live birth per treatment compared with conventional IVF. Despite its clinical success, there has been little information about the suitable conditions for human IVM. Therefore, improving developmental competency of immature oocytes continues to be an important concern of most IVM centers. Among many factors which affect efficacy of IVM, culture conditions are believed to be the most important factor, because different culture medium with changes of constituents can affect the oocyte maturation potential and subsequent embryonic development (Trounson et al., 2001). Currently, many different types of commercially available maturation media have been used in clinical IVM. They are commonly supplemented with hormone (recombinant FSH, hCG) and protein sources. Protein component may serve as a nitrogen source and act as a chelator of toxic metal ions and an antioxidant within culture media. In this respect, a development of well defined maturation medium supplemented with an efficient and safe protein source would improve IVM results. We previously reported that developmental competency of immature oocytes (either GV or MI) obtained from stimulated IVF cycles was comparable when matured in vitro with commercial G2 media supplemented by either human follicular fluids (hFF) or human serum albumin (HSA) (Jee et al., 2008). Our results suggest that hFF as a protein supplement for human in vitro maturation can be replaced by highly defined HSA. A development of well defined maturation medium should be continued in the effort to improve IVM results. More research is also needed to determine the roles of specific components and optimal culture conditions required in maturing oocytes. IVM of human oocytes retrieved from antral ovarian follicles is an emerging procedure quickly being incorporated into the realm of assisted reproductive technologies (ART). This new technology has several potential advantages over traditional controlled ovarian hyperstimulation for IVF, such as reduction of costs by minimizing gonadotropin and GnRH analogue use, elimination of OHSS, and simplicity of protocol. IVM of oocytes for ART in human beings still is undergoing refinement but currently is providing efficacy and safety outcome comparable to that of traditional IVF in recent selected studies. Implementing IVM into an established IVF practice is feasible and requires only a few simple adjustments. Crucial to the advancement and optimization of the technology is a better understanding of how to maximize immature oocyte developmental competence and endometrial receptivity.
더보기서지정보 내보내기(Export)
닫기소장기관 정보
닫기권호소장정보
닫기오류접수
닫기오류 접수 확인
닫기음성서비스 신청
닫기음성서비스 신청 확인
닫기이용약관
닫기학술연구정보서비스 이용약관 (2017년 1월 1일 ~ 현재 적용)
학술연구정보서비스(이하 RISS)는 정보주체의 자유와 권리 보호를 위해 「개인정보 보호법」 및 관계 법령이 정한 바를 준수하여, 적법하게 개인정보를 처리하고 안전하게 관리하고 있습니다. 이에 「개인정보 보호법」 제30조에 따라 정보주체에게 개인정보 처리에 관한 절차 및 기준을 안내하고, 이와 관련한 고충을 신속하고 원활하게 처리할 수 있도록 하기 위하여 다음과 같이 개인정보 처리방침을 수립·공개합니다.
주요 개인정보 처리 표시(라벨링)
목 차
3년
또는 회원탈퇴시까지5년
(「전자상거래 등에서의 소비자보호에 관한3년
(「전자상거래 등에서의 소비자보호에 관한2년
이상(개인정보보호위원회 : 개인정보의 안전성 확보조치 기준)개인정보파일의 명칭 | 운영근거 / 처리목적 | 개인정보파일에 기록되는 개인정보의 항목 | 보유기간 | |
---|---|---|---|---|
학술연구정보서비스 이용자 가입정보 파일 | 한국교육학술정보원법 | 필수 | ID, 비밀번호, 성명, 생년월일, 신분(직업구분), 이메일, 소속분야, 웹진메일 수신동의 여부 | 3년 또는 탈퇴시 |
선택 | 소속기관명, 소속도서관명, 학과/부서명, 학번/직원번호, 휴대전화, 주소 |
구분 | 담당자 | 연락처 |
---|---|---|
KERIS 개인정보 보호책임자 | 정보보호본부 김태우 | - 이메일 : lsy@keris.or.kr - 전화번호 : 053-714-0439 - 팩스번호 : 053-714-0195 |
KERIS 개인정보 보호담당자 | 개인정보보호부 이상엽 | |
RISS 개인정보 보호책임자 | 대학학술본부 장금연 | - 이메일 : giltizen@keris.or.kr - 전화번호 : 053-714-0149 - 팩스번호 : 053-714-0194 |
RISS 개인정보 보호담당자 | 학술진흥부 길원진 |
자동로그아웃 안내
닫기인증오류 안내
닫기귀하께서는 휴면계정 전환 후 1년동안 회원정보 수집 및 이용에 대한
재동의를 하지 않으신 관계로 개인정보가 삭제되었습니다.
(참조 : RISS 이용약관 및 개인정보처리방침)
신규회원으로 가입하여 이용 부탁 드리며, 추가 문의는 고객센터로 연락 바랍니다.
- 기존 아이디 재사용 불가
휴면계정 안내
RISS는 [표준개인정보 보호지침]에 따라 2년을 주기로 개인정보 수집·이용에 관하여 (재)동의를 받고 있으며, (재)동의를 하지 않을 경우, 휴면계정으로 전환됩니다.
(※ 휴면계정은 원문이용 및 복사/대출 서비스를 이용할 수 없습니다.)
휴면계정으로 전환된 후 1년간 회원정보 수집·이용에 대한 재동의를 하지 않을 경우, RISS에서 자동탈퇴 및 개인정보가 삭제처리 됩니다.
고객센터 1599-3122
ARS번호+1번(회원가입 및 정보수정)